Business
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026
RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference taking place in Philadelphia from May 17–20, 2026. Studies highlight the significant healthcare and quality-of-life burden associated with hereditary angioedema (HAE) in pediatric patients and their caregivers, demonstrating
About this update from Biocryst Pharmaceuticals, Inc.
[{"type":"image","alt":"BioCryst Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"BioCryst Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/9be0f0f5eacb522c15d80d31bd7eea85"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zbdbyUN7apmEYj4Oonisww--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9be0f0f5eacb522c15d80d31bd7eea85","width":300,"height":117},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/zbdbyUN7apmEYj4Oonisww--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9be0f0f5eacb522c15d80d31bd7eea85","width":300,"height":117}},"lazy":false},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference taking place in Philadelphia from May 17–20, 2026.","length":331,"tagName":"p"},{"type":"text","content":"Studies highlight the significant healthcare and quality-of-life burden associated with hereditary angioedema (HAE) in pediatric patients and their caregivers, demonstrating persistent unmet needs and the importance of optimized disease management to reduce healthcare utilization. Underscoring the role of outcomes research in rare diseases, the research draws on large U.S. insurance claims data and mixed-methods caregiver insights to examine both healthcare resource utilization and the day-to-day impact of pediatric HAE on caregivers.","length":540,"tagName":"p"},{"type":"text","content":"“Hereditary angioedema places a significant burden on children and the families caring for them, which is often underrecognized,” said Christina G. Kwong, MD, allergist and immunologist, Phoenix Children’s. “Understanding both the healthcare utilization impact and caregiver experience through real-world research is key to improving how we care for these kids.”","length":362,"tagName":"p"},{"type":"text","content":"BioCryst will present the following two poster presentations at the Pennsylvania Convention Center, Level 200, Exhibit Hall:","length":124,"tagName":"p"},{"type":"text","content":"Heal...